Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing.
Evaluate dalcetrapib's potential to prolong QT intervals in healthy subjects. This was a single-center, randomized, active and placebo-controlled, six-sequence, three-period cross-over study. Participants [18-65 years; body mass index (BMI) 18-30 kg/m2] were randomized to daily doses of dalcetrapib...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 66; no. 8; pp. 775 - 784 |
|---|---|
| Autores principales: | , , , |
| Formato: | clinical trial research Journal Article |
| Publicado: |
Springer Nature
Aug2010
|
| Acceso en línea: | Ver este registro en EBSCOhost |